Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.

about

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

P2860

Q39426952-D995DD81-9669-48E4-B840-E73DD8456BBE Q47966525-ADD46CF1-1E6C-42C8-AAA7-CC960C2E4888

P2860

Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.

Item

http://www.wikidata.org/entity/Q38931421

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Umeclidinium Plus Vilanterol V ...... Randomized Controlled Trials.

@en

type

Item

label

Umeclidinium Plus Vilanterol V ...... Randomized Controlled Trials.

@en

prefLabel

Umeclidinium Plus Vilanterol V ...... Randomized Controlled Trials.

@en

P1476

Umeclidinium Plus Vilanterol V ...... Randomized Controlled Trials.

@en

P2093

Chun-Juan Zhai

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Shu-Juan Jiang

http://www.w3.org/2001/XMLSchema#string

Yao Liu

http://www.w3.org/2001/XMLSchema#string

Yi Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.

Recent advances in COPD disease management with fixed-dose long-acting combination therapies.

A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis.

P304

865-875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S40261-016-0449-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27539612

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

placebo

Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.

about

P2860

P2860

Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921